 HAMILTON, BERMUDA ACCESSWIRE October 14, 2021 Altamira Therapeutics Ltd. NASDAQ:CYTO Altamira or the Company, a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its 510k application for premarket clearance filed with the U.S. Food and Drug Administration FDA for its BentrioTM nasal spray for protection against airborne allergens has cleared the Agencys acceptance review. 